Qimian Su - GeneFerm Biotechnology Head of Finance & Accounting
| 1796 Stock | TWD 50.10 0.10 0.20% |
Insider
Qimian Su is Head of Finance & Accounting of GeneFerm Biotechnology Co since 2005.
| Tenure | 19 years |
| Phone | 886 6 510 9001 |
| Web | https://www.geneferm.com |
GeneFerm Biotechnology Management Efficiency
The company has return on total asset (ROA) of 0.0534 % which means that it generated a profit of $0.0534 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1211 %, meaning that it generated $0.1211 on every $100 dollars invested by stockholders. GeneFerm Biotechnology's management efficiency ratios could be used to measure how well GeneFerm Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| ChingChi Chen | Kinko Optical Co | N/A | |
| ChiaoLi Pan | Giant Manufacturing Co | N/A | |
| Wenlong Tseng | Chong Hong Construction | N/A | |
| KuoHsing Huang | Chong Hong Construction | N/A | |
| Yaomin Lee | Chong Hong Construction | N/A | |
| YuonChan Liu | Giant Manufacturing Co | N/A | |
| JungShan Wang | Chong Hong Construction | N/A | |
| JinTze Wu | Chong Hong Construction | N/A | |
| PiYu Wang | Giant Manufacturing Co | N/A | |
| PoFong Lin | Great Taipei Gas | N/A | |
| LiangChang Chou | Kinko Optical Co | N/A | |
| ChinPiao Liu | Giant Manufacturing Co | N/A | |
| Jin Zheng | Giant Manufacturing Co | N/A | |
| ShengChang Chang | Giant Manufacturing Co | N/A | |
| MaoChing Chen | Chong Hong Construction | N/A | |
| ChiHao Wu | Great Taipei Gas | N/A | |
| ChingHsin Yen | Giant Manufacturing Co | N/A | |
| Kam Koo | Giant Manufacturing Co | N/A | |
| ChenTung Chen | Great Taipei Gas | N/A | |
| ZhengHua Zhang | Great Taipei Gas | N/A | |
| MingShan Zhou | Great Taipei Gas | N/A | |
Management Performance
| Return On Equity | 0.12 | |||
| Return On Asset | 0.0534 |
GeneFerm Biotechnology Leadership Team
Elected by the shareholders, the GeneFerm Biotechnology's board of directors comprises two types of representatives: GeneFerm Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GeneFerm. The board's role is to monitor GeneFerm Biotechnology's management team and ensure that shareholders' interests are well served. GeneFerm Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GeneFerm Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Frank Hsiao, Deputy General Manager-Sales & Marketing Division | ||
| Qimian Su, Head of Finance & Accounting | ||
| Zongmin Chen, Independent Director | ||
| Grance Chang, Chairman of the Board | ||
| Benlin Chen, Director | ||
| Yiren Ji, Director | ||
| Jiajun Hong, Director | ||
| Shixun Lin, Independent Director | ||
| Fangcai Qiu, Independent Director | ||
| Nuzhu Qiu, Director | ||
| JinnDer Jin, General Manager, Director | ||
| Yih Yao, Director |
GeneFerm Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GeneFerm Biotechnology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.12 | |||
| Return On Asset | 0.0534 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.17 % | |||
| Current Valuation | 2.48 B | |||
| Shares Outstanding | 41.46 M | |||
| Shares Owned By Insiders | 57.17 % | |||
| Price To Earning | 53.28 X | |||
| Price To Book | 2.94 X | |||
| Price To Sales | 4.16 X |
Pair Trading with GeneFerm Biotechnology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if GeneFerm Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GeneFerm Biotechnology will appreciate offsetting losses from the drop in the long position's value.Moving against GeneFerm Stock
| 0.62 | 6620 | Handa Pharmaceuticals | PairCorr |
| 0.5 | 4114 | Synmosa Biopharma | PairCorr |
| 0.47 | 6785 | Alar Pharmaceuticals | PairCorr |
| 0.36 | 3008 | LARGAN Precision | PairCorr |
| 0.31 | 6539 | DV Biomed | PairCorr |
The ability to find closely correlated positions to GeneFerm Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace GeneFerm Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back GeneFerm Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling GeneFerm Biotechnology Co to buy it.
The correlation of GeneFerm Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as GeneFerm Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if GeneFerm Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for GeneFerm Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for GeneFerm Stock Analysis
When running GeneFerm Biotechnology's price analysis, check to measure GeneFerm Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneFerm Biotechnology is operating at the current time. Most of GeneFerm Biotechnology's value examination focuses on studying past and present price action to predict the probability of GeneFerm Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneFerm Biotechnology's price. Additionally, you may evaluate how the addition of GeneFerm Biotechnology to your portfolios can decrease your overall portfolio volatility.